FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.
Q&A: Retail, Independent Pharmacies Continue to Call for Improved Reimbursement Practices
June 30th 2025Rick Gates, chief pharmacy officer at Walgreens and chairman of the National Association of Chain Drug Stores, discussed the current status of retail pharmacies and the way they are reimbursed.